

Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab

Hagström, Emil; Steg, P. Gabriel; Szarek, Michael; Bhatt, Deepak L.; Bittner, Vera A.; Danchin, Nicolas; Diaz, Rafael; Goodman, Shaun G.; Harrington, Robert A.; Jukema, J. Wouter; Liberopoulos, Evangelos; Marx, Nikolaus; **Viigimaa, Margus** Circulation 2022 / p. 657 - 672 <https://doi.org/10.1161/CIRCULATIONAHA.121.057807> [Journal metrics at Scopus](#) [Article at Scopus](#) [Journal metrics at WOS](#) [Article at WOS](#)

Effects of alirocumab on cardiovascular events after coronary bypass surgery

Goodman, Shaun G.; Aylward, Philip E.; Szarek, Michael; **Viigimaa, Margus** Journal of the American College of Cardiology 2019 / p. 1177–1186 : ill <https://doi.org/10.1016/j.jacc.2019.07.015>

Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol

Schwartz, Gregory G.; Szarek, Michael; Bittner, Vera A.; Diaz, Rafael; Goodman, Shaun G.; **Viigimaa, Margus** Journal of the American College of Cardiology 2021 / p. 421–433 : ill <https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102> <https://doi.org/10.1016/j.jacc.2021.04.102>